Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design-Reference-Cited by-同舟云学术

Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design

Published:2024-06 Issue: Volume:209 Page:115301
ISSN:0169-409X
Container-title:Advanced Drug Delivery Reviews
language:en
Short-container-title:Advanced Drug Delivery Reviews

Author:

Mathias Neil,Huille Sylvain,Picci Marie,Mahoney Robert P.,Pettis Ronald J.,Case Brian,Helk Bernhard,Kang David,Shah Ronak,Ma Junchi,Bhattacharya Deep,Krishnamachari Yogita,Doucet Dany,Maksimovikj Nathalie,Babaee Sahab,Garidel Patrick,Esfandiary Reza,Gandhi Rajesh

Publisher

Elsevier BV

Reference182 articles.

1. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer;De Cock;Cancer Med,2016

2. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities;Bittner;BioDrugs,2018

3. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

4. Payer perspectives on intravenous versus subcutaneous administration of drugs;Epstein;Clinicoecon Outcomes Res,2021

5. An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs;Launay-Vacher;Cancer Chemother Pharmacol,2013

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design;Advanced Drug Delivery Reviews;2024-06